November 1, 2023 02:38 PM EDTUpdated 03:57 PM
Pharma

Mer­ck­'s Keytru­da gets bil­iary tract can­cer ap­proval, brings in more pos­i­tive sur­vival da­ta in re­nal car­ci­no­ma

Katherine Lewin

News Reporter

Mer­ck is kick­ing off No­vem­ber with two pos­i­tive re­sults for its an­ti-PD-1 ther­a­py Keytru­da — a win in a sec­ondary end­point of over­all sur­vival in re­nal …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

WuXi AppTec will sell cell and gene ther­a­py busi­ness to pri­vate eq­ui­ty firm

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

J&J part­ners on STAT6; As­traZeneca, Dai­ichi with­draw lung can­cer drug EMA app

BioN­Tech set­tles with NIH, UPenn in Covid vac­cine dis­putes and will pay roy­al­ties

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

A service from the Financial Times